arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Anixa Biosciences Inc

ANIX
$2.75 ▼ -0.03 (-1.08%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
62 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Anixa Biosciences Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $94.0M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -14.9% ↘
FCF / Share $-0.05 →
Trailing P/E —
Price / Book 6.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

62-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-2.61M
↓ -15.4% —
Operating Margin Operating profit as % of sales
-435.7%
↓ -133.3% —
FCF / Share Free cash flow per share
$-0.05
— +0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Cash Quality ↑
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 16 years · 62 quarters